Articles related to CAR-T THERAPY
The New England Journal of Medicine
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Twenty-seven (27) children with heavily pretreated neuroblastoma (12 with refractory disease, 14 with relapsed disease, and one with a complete response at the end of first-line therapy) were enrolled in this academic, phase 1-2 clinical trial to test autologous, third-generation GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01). The use of GD2-CART01 in the treatment of high-risk neuroblastoma was feasible and safe. Treatment-related toxic effects emerged, and the suicide gene was activated to control side effects. GD2-CART01 may have long-term antitumor activity.
Oncology, Medical April 10th 2023
The New England Journal of Medicine
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
In this international, phase 3 trial, patients with large B-cell lymphoma who were refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy were randomly assigned to receive axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard care in a 1:1 ratio. Axi-cel therapy resulted in significant improvements in event-free survival and response when compared to standard care, with the expected level of high-grade toxic effects.
Hematology March 13th 2023
Selecting CAR T-cell Therapy for Patients with Late Relapsed Multiple Myeloma
Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, cell therapy experts, and other HCPs actively involved in the care of patients with multiple myeloma should be better able to:
Hematology March 6th 2023
Roswell Park Researchers Present New Approach to Understanding Challenging CAR T-Cell Toxicities
Payal Goala, MS, BS, a pre-doctoral fellow at Roswell Park Comprehensive Cancer Center, presented research findings at the 64th annual meeting of the American Society of Hematology (ASH), held December 10–13 in New Orleans, Louisiana. Her work may help address neutropenia and cytokine release syndrome, two serious side effects of chimeric antigen receptor (CAR) T-cell therapy. The research is being hailed as a “significant advancement” in the knowledge of these toxicities and is expected to help patients receiving CAR-T therapy live better lives.
Oncology, Medical February 27th 2023
Mantle Cell Lymphoma: Optimizing Current Therapies
The diagnosis and treatment of mantle cell lymphoma are covered in this podcast by Jonathon Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine. He also discusses how BTK inhibitors and CAR T-cell therapy are changing the treatment landscape and what he expects will be presented at upcoming conferences.
Oncology, Medical January 3rd 2023
Hematology, ASH Education Program
Transformed Lymphoma: What Should I Do Now?
An important development in patient treatment occurs when indolent lymphomas develop an aggressive histology, which necessitates a shift in therapy. Although the prevalence of transformation is generally falling, it is still a very dangerous situation with a poor prognosis when compared to patients who do not have transformation. CAR-T has helped, but overall, the prognosis for patients with transformed lymphomas is still quite poor, especially if hematopoietic stem cell transplant (HSCT) or cellular therapy methods are not accessible or are ineffective. The top priority at this time should be to enroll the patient in a clinical trial.
Hematology December 19th 2022